Ken Griffin Mereo Biopharma Group PLC Transaction History

Citadel Advisors LLC

$483 Billion
Q2 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Mereo Biopharma Group PLC stock. As of the latest transaction made, Citadel Advisors LLC holds 27,900 shares of MREO stock, worth $118,575. This represents 0.0% of its overall portfolio holdings.

Number of Shares

27,900

Previous 33,000 15.45%

Holding current value

$118,575

Previous $108,000 7.41%

% of portfolio

0.0%

Previous 0.0%

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$2.58 - $4.25 $941,911 - $1.55 Million	365,082 Added 831.49%	408,989 $1.47 Million
Q1 2024 May 15, 2024	SELL	$2.3 - $4.05 $646,097 - $1.14 Million	-280,912 Reduced 86.48%	43,907 $144,000
Q4 2023 Feb 14, 2024	SELL	$1.19 - $2.42 $2.28 Million - $4.64 Million	-1,917,606 Reduced 85.51%	324,819 $750,000
Q3 2023 Nov 14, 2023	BUY	$1.15 - $1.67 $545,079 - $791,549	473,982 Added 26.8%	2,242,425 $2.89 Million
Q2 2023 Aug 14, 2023	SELL	$0.79 - $1.43 $1.01 Million - $1.83 Million	-1,279,517 Reduced 41.98%	1,768,443 $2.33 Million
Q1 2023 May 15, 2023	SELL	$0.71 - $1.22 $10,204 - $17,533	-14,372 Reduced 0.47%	3,047,960 $2.16 Million
Q4 2022 Feb 14, 2023	SELL	$0.5 - $1.01 $6,777 - $13,690	-13,555 Reduced 0.44%	3,062,332 $2.3 Million
Q3 2022 Nov 14, 2022	BUY	$0.82 - $1.73 $256,218 - $540,559	312,462 Added 11.31%	3,075,887 $2.65 Million
Q2 2022 Aug 15, 2022	SELL	$0.33 - $1.69 $377,160 - $1.93 Million	-1,142,910 Reduced 29.26%	2,763,425 $3.1 Million
Q1 2022 May 16, 2022	SELL	$1.04 - $1.7 $98,258 - $160,614	-94,479 Reduced 2.36%	3,906,335 $4.38 Million
Q4 2021 Feb 14, 2022	SELL	$1.51 - $2.59 $111,447 - $191,157	-73,806 Reduced 1.81%	4,000,814 $6.4 Million
Q3 2021 Nov 15, 2021	BUY	$2.2 - $3.17 $2.47 Million - $3.55 Million	1,120,552 Added 37.93%	4,074,620 $9.86 Million
Q2 2021 Aug 16, 2021	BUY	$2.94 - $4.08 $1.52 Million - $2.11 Million	516,810 Added 21.2%	2,954,068 $9.36 Million
Q1 2021 May 17, 2021	SELL	$2.6 - $4.43 $4.36 Million - $7.43 Million	-1,678,197 Reduced 40.78%	2,437,258 $8.21 Million
Q4 2020 Feb 16, 2021	BUY	$1.95 - $3.6 $7.99 Million - $14.8 Million	4,097,346 Added 22626.02%	4,115,455 $14.7 Million
Q3 2020 Nov 16, 2020	BUY	$2.55 - $3.29 $46,177 - $59,578	18,109 New	18,109 $47,000

Others Institutions Holding MREO

# of Institutions

Shares Held

102M

Call Options Held

121K

Put Options Held

208K

View Full List

About Mereo Biopharma Group plc

Ticker MREO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 124,986,000
Market Cap $531M
Description
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the tr...

More about MREO

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account